{
    "Disease activity (follow up: 6 months; assessed with: DAS 28-ESR (Lower values – > benefit) (MCID -1.17)": {
        "No of studies": "1",
        "Study design": "randomised trials",
        "Risk of bias": "not serious",
        "Inconsistency": "not serious",
        "Indirectness": ["serious", "a"],
        "Imprecision": "not serious",
        "Other considerations": "none",
        "Nº of patients": {
            "csDMARD triple therapy": "132",
            "csDMARD monotherapy": "379"
        },
        "Effect": {
            "Relative (95% CI)": "-",
            "Absolute (95% CI)": "MD 0.64 lower (0.95 lower to 0.33 lower)"
        },
        "Certainty": "⨁⨁⨁◯ MODERATE",
        "Importance": "CRITICAL"
    },

    "Disease activity (follow up: 6 months; assessed with: ACR 20)": {
        "No of studies": "1",
        "Study design": "randomised trials",
        "Risk of bias": "not serious",
        "Inconsistency": "not serious",
        "Indirectness": ["serious", "a"],
        "Imprecision": "not serious",
        "Other considerations": "none",
        "Nº of patients": {
            "csDMARD triple therapy": ["73/132 (55.3%)", "b"],
            "csDMARD monotherapy": ["150/379 (39.6%)", "c"]
        },
        "Effect": {
            "Relative (95% CI)": "RR 1.40 (1.15 to 1.70)",
            "Absolute (95% CI)": "158 more per 1,000 (from 59 more to 277 more)"
        },
        "Certainty": "⨁⨁⨁◯ MODERATE",
        "Importance": "CRITICAL"
    },

    "Disease activity (follow up: 6 months; assessed with: ACR 50)": {
        "No of studies": "1",
        "Study design": "randomised trials",
        "Risk of bias": "not serious",
        "Inconsistency": "not serious",
        "Indirectness": ["serious", "a"],
        "Imprecision": "not serious",
        "Other considerations": "none",
        "Nº of patients": {
            "csDMARD triple therapy": ["41/132 (31.1%)", "b"],
            "csDMARD monotherapy": ["73/379 (19.3%)", "c"]
        },
        "Effect": {
            "Relative (95% CI)": "RR 1.61 (1.16 to 2.24)",
            "Absolute (95% CI)": "117 more per 1,000 (from 31 more to 239 more)"
        },
        "Certainty": "⨁⨁⨁◯ MODERATE",
        "Importance": "CRITICAL"
    },

    "Disease activity (follow up: 6 months; assessed with: ACR 70)": {
        "No of studies": "1",
        "Study design": "randomised trials",
        "Risk of bias": "not serious",
        "Inconsistency": "not serious",
        "Indirectness": ["serious", "a"],
        "Imprecision": ["serious", "d"],
        "Other considerations": "none",
        "Nº of patients": {
            "csDMARD triple therapy": ["11/132 (8.3%)", "b"],
            "csDMARD monotherapy": ["13/379 (3.4%)", "c"]
        },
        "Effect": {
            "Relative (95% CI)": "RR 2.43 (1.12 to 5.29)",
            "Absolute (95% CI)": "49 more per 1,000 (from 4 more to 147 more)"
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "CRITICAL"
    }
}